INREBIC® (fedratinib) logo

INREBIC® (fedratinib) is a prescription medicine used to treat adults with certain types of myelofibrosis (MF). It is not known if INREBIC is safe and effective in children.

Prescribing Information

This site is intended for US audiences only.

This website is best viewed using the horizontal display on your tablet device.

This website is best viewed using the vertical display on your mobile device.

Resources & Support

Be prepared with helpful resources and find support to guide you and your loved ones along your journey.

Not an actual patient.

Resources & Support

Be prepared with helpful resources and find support to guide you and your loved ones along your journey.

Not an actual patient.

Access & financial resources

Patient Access, Reimbursement, and Co-Pay Support

Available Through

Bristol Myers Squibb is committed to helping patients gain access to their prescribed BMS medications. That’s why we offer the BMS Access Support® program, which provides resources to help patients understand their insurance coverage and find information on sources of financial support, including co-pay assistance for eligible commercially insured patients. For more information, ask your doctor, visit BMS Access Support, or call BMS Access Support® at 1-800-861-0048, 8 AM to 8 PM ET,
Monday–Friday.

Important questions to ask your doctor

It’s important to be up front about what you’re experiencing. Honest communication with your care team can help you make informative choices about your health. It also helps to build a strong partnership. A strong team can mean more support for you.

Try using these questions to get the information you need. Consider taking notes as you hear the answers to refer to after your appointment.

Talk about your symptoms.

  • I’m on treatment, but I’m still feeling tired, have pain, etc.
  • I have symptoms such as nausea, diarrhea, itchiness, etc. Is there anything you can suggest to help manage them?
  • Be as specific and open as you can with your HCP by asking questions and communicating specific information about the symptoms you might be experiencing.
  • Should I expect to feel better or is this just how it’s going to be?

Ask about your options.

  • What are my treatment options?
  • What do you consider when determining the appropriate treatment for me?

Ask about INREBIC.

  • What are the side effects with INREBIC that I should be aware of?
  • Are there any side effects that I experience which signal I call you immediately?
  • Does INREBIC interact with any other medications I’m currently taking?
  • What can I expect when taking INREBIC?

Ask other important questions about INREBIC.

  • Will my health insurance pay for INREBIC?
  • What if my INREBIC prescription is denied by my health insurance?
  • Does INREBIC have a patient support program?
  • How do I get my INREBIC prescription through a specialty pharmacy?

Ask loved ones for help.

  • Would you come with me to my appointments?
  • Can you help me prepare for my appointments?
  • Can you take notes while I listen to what the doctor says?
  • Will you help me remember to take my medication?
  • Can you help me track or remind me to track my symptoms?
  • Can you help me discuss or remind me to discuss my questions with my doctor?
Hypothetical doctor smiling while touching the shoulder of a hypothetical INREBIC® (fedratinib) patient with myelofibrosis Hypothetical doctor smiling while touching the shoulder of a hypothetical INREBIC® (fedratinib) patient with myelofibrosis

Not an actual patient.

Find MF organizations and advocacy groups

This list of independent organizations is provided as a resource for obtaining support and information related to MF.

This list does not indicate endorsement by Bristol Myers Squibb of an organization or its communications.

Reach out to others

Living with myelofibrosis may be particularly stressful for patients. They might not know how to talk about it, and it may
be hard to know exactly what kind of emotional support they need.

  • Be realistic about what you can do, and learn how to pass on the responsibilities to others if necessary
  • Tell people how they can help, as they may not be aware of what caregiving involves
  • Work with friends and family to make a plan of what needs to get done
  • Let go of tasks that can wait until later because you can always go back to them at another time

Indication and Important Safety Information

Indication

What is INREBIC® (fedratinib)?
INREBIC is a prescription medicine used to treat adults with certain types of myelofibrosis (MF). It is not known if INREBIC is safe and effective in children.

Important Safety Information

What is the most important information I should know about INREBIC?

INREBIC may cause serious side effects, including:

  • Encephalopathy (including Wernicke’s encephalopathy). A serious and sometimes fatal neurological problem called encephalopathy (including Wernicke’s encephalopathy) has happened in some people who take INREBIC. Wernicke’s encephalopathy is a neurologic emergency that can happen if you do not have enough Vitamin B1 (thiamine) in your body. Your healthcare provider will do a blood test to check your Vitamin B1 level and treat you with Vitamin B1 if your level is too low before starting treatment with INREBIC. Your healthcare provider may also check your Vitamin B1 level during treatment with INREBIC. You should take a Vitamin B1 supplement (100 mg of thiamine) during treatment with INREBIC. Your healthcare provider may tell you to stop taking INREBIC if you develop side effects during treatment with INREBIC.

Get emergency medical help right away if you develop the following:

  • confusion, memory problems, or drowsiness
  • problems with balance and movement, such as difficulty walking
  • eye problems, such as double or blurred vision or abnormal eye movements

Call your healthcare provider right away if you experience diarrhea, nausea, vomiting, and weight loss that does not get better with treatment.

Before taking INREBIC, tell your healthcare provider about all your medical conditions, including if you:

  • have low Vitamin B1 (thiamine) levels
  • have low red blood cell or platelet counts
  • have or have had liver problems
  • have or have had kidney problems
  • are a current or past smoker
  • have had a blood clot, heart attack, other heart problems, or stroke
  • have or have had any other cancer
  • are pregnant or plan to become pregnant. It is not known if INREBIC may harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if INREBIC passes into your breast milk. You should not breastfeed during treatment with INREBIC and for at least 1 month after your last dose. Talk to your healthcare provider about the best way to feed your baby during treatment with INREBIC.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Taking INREBIC with certain other medicines may cause side effects from INREBIC or from the other medicine and may affect the way that INREBIC works. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

How should I take INREBIC?

  • Take INREBIC exactly as your healthcare provider tells you to. Do not change your dose or stop taking INREBIC unless your healthcare provider tells you to.
  • Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with INREBIC if you develop side effects.
  • Take INREBIC 1 time each day.
  • Take INREBIC with or without food. Taking INREBIC with a high fat meal may help to reduce nausea and vomiting symptoms.
  • Take Vitamin B1 (thiamine 100 mg) by mouth daily to prevent low Vitamin B1 levels during treatment with INREBIC.
  • If you miss a dose of INREBIC, skip the missed dose and take your usual dose the next day at your regularly scheduled time. Do not take 2 doses to make up for the missed dose.

What are the possible side effects of INREBIC?
INREBIC may cause serious side effects, including:

  • Low blood cell counts. INREBIC may cause new or worsening low red blood cell counts (anemia) and low platelet counts (thrombocytopenia) in some people. You may need a blood transfusion if your blood counts drop too low. Your healthcare provider will do blood tests to check your blood counts before you start and during treatment with INREBIC. Tell your healthcare provider if you develop any bleeding or bruising during treatment with INREBIC.
  • Diarrhea, nausea, and vomiting. Your healthcare provider may give you certain medicines to help treat your diarrhea, nausea, and vomiting. Call your healthcare provider or get emergency medical help right away if you have diarrhea, nausea, or vomiting that does not get better with treatment.
  • Liver problems. INREBIC may cause increased liver enzymes. Your healthcare provider will do blood tests to check your liver function before starting and during treatment with INREBIC.
  • Amylase and lipase increases. You may have increases in your blood amylase or lipase levels that may indicate a problem with your pancreas. Your healthcare provider will do blood tests to check your amylase or lipase levels before starting and during treatment with INREBIC.
  • Major cardiac events such as heart attack, stroke, or death. An increased risk of major cardiac events has happened in people, especially those who have cardiovascular risk factors and who are current or past smokers, while taking another Janus Kinase (JAK)-inhibitor to treat rheumatoid arthritis. Get emergency help right away if you have any symptoms of a heart attack or stroke while taking INREBIC, including:
    • discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back
    • severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
    • pain or discomfort in your arms, back, neck, jaw, or stomach
    • shortness of breath with or without chest discomfort
    • breaking out in a cold sweat
    • nausea or vomiting
    • feeling lightheaded
    • weakness in one part or on one side of your body
    • slurred speech
  • Blood clots. Increased risk of blood clots in the veins of the legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) have happened in people taking another JAK-inhibitor for rheumatoid arthritis and may be life-threatening. Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with INREBIC, including:
    • swelling, pain, or tenderness in one or both legs
    • sudden unexplained chest or upper back pain
    • shortness of breath or difficulty breathing
  • New (secondary) cancers. People who take another JAK-inhibitor for rheumatoid arthritis have an increased risk of new (secondary) cancers, including lymphoma and other cancers, except nonmelanoma skin cancer. People who smoke or who smoked in the past have an added increased risk of new cancers.

The most common side effects of INREBIC include:

  • diarrhea
  • nausea
  • low red blood cell counts (anemia)
  • vomiting

These are not all of the possible side effects of INREBIC.

Call your doctor for medical advice about side effects. You may report side effects to FDA at
1-800-FDA-1088.

Please see full Prescribing Information for INREBIC including BOXED WARNING and Medication Guide.